While biopharmaceutical and med-tech executives were wheeling, dealing and dining beneath the logo of a 24-karat gold pill at the 37th Annual J.P. Morgan (JPM) Healthcare Conference, patients continued to cut back on their life-saving drugs because they couldn't afford their medications. Read More
SAN FRANCISCO - "Fast" seemed the watchword for Takeda Pharmaceutical Co. Ltd. this week, as it officially closed its $62 billion acquisition of rare disease specialist Shire plc. "We don't want to lose momentum in the business," Takeda President CEO Christophe Weber said during a Tuesday presentation at the J.P. Morgan Healthcare Conference. "We want to integrate the two companies very quickly and to really gain the full benefit of the combination as soon as possible," he said. Read More
LONDON – Cell and gene therapy powered ahead across the globe in 2018, with companies in the sector raising $13.3 billion, an increase of 73 percent over $7.5 billion raised in 2017, and more than three times the 2016 total of $4.2 billion. Read More
Researchers have identified a single nucleotide polymorphism (SNP) that affected whether the diabetes drug Avandia (rosiglitazone, GlaxoSmithKline plc) would cause a rise in cholesterol levels. Read More
Reporting at the 11th Annual T-Cell Lymphoma Forum in La Jolla, Calif., Miragen Therapeutics Inc. provided phase I data on cobomarsen in cutaneous T-cell lymphoma (CTCL) and adult T-cell leukemia/lymphoma (ATLL) along with a first look at prospects in diffuse large B-cell lymphoma (DLBCL). Read More
Diamedica Therapeutics Inc., of Minneapolis, applied for voluntarily delisting of its shares from the TSX Venture Exchange following an IPO on Nasdaq last month. The delisting is expected to become effective at the close of business on Jan. 18. Read More
Summit Therapeutics plc, of Oxford, U.K., completed its $25 million sale of 78.125 million new shares represented by 15.625 American depositary shares, which was approved by shareholders at the company's general meeting on Jan. 4. Read More
With a vote of 243-183, the U.S. House passed a bill Thursday to fund the FDA, along with the Department of Agriculture, for the rest of fiscal 2019, but it's unlikely the agency will be fully operational any time soon. Read More
